Navigation Links
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
Date:1/4/2008

ck,

non-fatal stroke or cardiovascular death (p<0.001).

-- 52 percent reduction compared with clopidogrel in stent thrombosis

(p<0.0001).

-- 30 percent relative risk reduction compared to clopidogrel in a subset

of patients with diabetes (p<0.001) on the composite endpoint of non-

fatal heart attack, non-fatal stroke, or cardiovascular death.

Risk reductions in the primary composite endpoint with prasugrel compared to clopidogrel were seen as early as three days and continued to diverge for 15 months (the duration of the trial.)

Though the incidence of non-coronary artery bypass grafting(non-CABG) bleeding in TRITON was low in both the prasugrel and clopidogrel treatment groups, prasugrel-treated patients experienced significantly higher non-CABG major bleeding (2.2% vs. 1.7%, respectively) and higher rates of life- threatening bleeding (1.3% vs. 0.8%, respectively). Death from cardiovascular causes (2% vs. 2.2%, respectively) and all-cause death (2.8% vs. 2.9%, respectively) was comparable among prasugrel-treated patients and clopidogrel- treated patients. The overall results demonstrated that for every 1,000 patients treated with prasugrel as compared with clopidogrel, there were 22 fewer patients with heart attacks and five more non-CABG-related TIMI major bleeds.

"Given the overall results from TRITON, this submission is particularly meaningful considering that cardiovascular disease is the leading cause of death in the United States and worldwide, killing 16.7 million people each year," said John Alexander, M.D., M.P.H., global head of research and development, Daiichi Sankyo Company, Limited.

Acute heart attacks and unstable angina, called acute coronary syndrome, affect more than 840,000 Americans each year and 800,000 people in Europe.(i,ii) Utilizing current medical interventions and treatments, 300,000 people continue to experience recurrent heart attacks and 450,000 people die fro
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
2. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
3. Lilly Declares Fourth-Quarter Dividend
4. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
5. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
6. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Cephalon Submits Supplemental New Drug Application for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (HZDR), the Vienna University of Technology and the ... nearly perfect semiconductor crystals into a silicon nanowire. ... very fast and multi-functional processing units can be ... The research results will be published in the ... considered the cornerstone of future chip technology, but ...
(Date:7/23/2014)... 23, 2014  Having the right people at the ... accelerating business growth and achieving clinical and operational goals. ... Leadership Summit, July 20-22, 2014, in San ... executives and healthcare experts discussing how partnerships have positively ... President & Chief Executive Officer of Cape Regional Medical ...
(Date:7/23/2014)... - BioAmber Inc. (NYSE: BIOA ), ... that the underwriters of its common stock offering ... additional 420,000 shares of common stock at the ... underwriting discounts and commissions, in connection with its ... of common stock, bringing the expected net proceeds ...
(Date:7/23/2014)... -- China Cord Blood Corporation (NYSE: CO ) ("CCBC" ... cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem ... company catering to the mother and child segment, today announced that ... PRC, Singapore , Hong Kong ... the Philippines and Malaysia ...
Breaking Biology Technology:A crystal wedding in the nanocosmos 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4
... 24 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it will hold a conference call to discuss,the ... update,including an update on the clinical development plan ... Ph.D., chairman and chief,executive officer, Ronald A. Martell, ...
... Ill., July 24 Sagent Pharmaceuticals, Inc.,a privately-held ... ceftazidime for injection, USP, a semisynthetic,broad-spectrum, beta-lactam antibiotic. ... dose vials and 6g pharmacy bulk package vials. ... in the United States were,approximately $45.7 million., ...
... Company reports double-digit sales and earnings growth, ... LLY ) today announced financial results for ... presented on a reported basis. Reported,results were prepared ... include all sales and expenses recognized by the,company ...
Cached Biology Technology:Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31 2Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP 2Lilly Reports Solid Second-Quarter Results 2Lilly Reports Solid Second-Quarter Results 3Lilly Reports Solid Second-Quarter Results 4Lilly Reports Solid Second-Quarter Results 5Lilly Reports Solid Second-Quarter Results 6Lilly Reports Solid Second-Quarter Results 7Lilly Reports Solid Second-Quarter Results 8Lilly Reports Solid Second-Quarter Results 9Lilly Reports Solid Second-Quarter Results 10Lilly Reports Solid Second-Quarter Results 11Lilly Reports Solid Second-Quarter Results 12Lilly Reports Solid Second-Quarter Results 13Lilly Reports Solid Second-Quarter Results 14Lilly Reports Solid Second-Quarter Results 15Lilly Reports Solid Second-Quarter Results 16Lilly Reports Solid Second-Quarter Results 17Lilly Reports Solid Second-Quarter Results 18Lilly Reports Solid Second-Quarter Results 19Lilly Reports Solid Second-Quarter Results 20Lilly Reports Solid Second-Quarter Results 21
(Date:7/23/2014)... Canada has issued a high health risk warning for ... the region due to forest fires. In the ... drifting eastward along normal wind patterns. Fire is ... from fires is not quite so obvious and its ... type of fire (forest, brush, crop, structure, tires, waste ...
(Date:7/23/2014)... DC -- The planet,s soil releases about 60 billion ... is far more than that released by burning fossil ... This enormous release of carbon is balanced by carbon ... other plant matter, as well as by the underground ... have documented that rising temperatures increase the rate of ...
(Date:7/23/2014)... local and national governments struggle to deal with ever-growing ... refining the picture of just how much there is ... ACS journal Environmental Science & Technology , their ... developed countries discard floods into just seven developing countries ... who live there. , Knut Breivik and colleagues note ...
Breaking Biology News(10 mins):Climate change and the soil 2
... State University have solved a long-standing conundrum about ... way into limestone, sand grains, mussel shells, coral ... According to the lead investigator, ASU professor ... what is "at the heart of an erosive ...
... sugar may be enough to cool a hot temper, at least ... found that people who drank a glass of lemonade sweetened with ... than did people who consumed lemonade with a sugar substitute. ... simple sugar found in the bloodstream that provides energy for the ...
... 30, 2010Access to quality reproductive healthcare for women around ... human rights, freedom, equity, and right to control her ... Health in the current issue of Journal of Women,s ... Inc., explores the compelling medical, socioeconomic, and gender-based factors ...
Cached Biology News:Mystery dissolves with calcium pump discovery 2Mystery dissolves with calcium pump discovery 3Researchers find link between sugar, diabetes and aggression 2Researchers find link between sugar, diabetes and aggression 3Researchers find link between sugar, diabetes and aggression 4Ensuring the rights of women worldwide to reproductive health care 2
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
...
Biology Products: